Modeling and simulation as a tool to bridge efficacy and safety data in special populations

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 2, 2013, Pages

  Harnisch, L ^a   Shepard, T ^b,c   Pons, G ^c,d   Della Pasqua, O ^e  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONCEPTUAL FRAMEWORK; DATA BASE; DECISION MAKING; DOSE CALCULATION; DRUG SAFETY; DRUG USE; EVIDENCE BASED PRACTICE; MEDICINE; PRIORITY JOURNAL; REGISTRATION; REVIEW; RISK ASSESSMENT;

EID: 84881137095     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.6     Document Type: Review

References (10)

1. Hoaglin, D.C. et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part Value Health 14, 429-437 (2011).
2. Jones, B. et al.; PSI Health Technology Special Interest Group, Evidence Synthesis subteam. Statistical approaches for conducting network meta-analysis in drug development. Pharm. Stat. 10, 523-531 (2011).
3. Manolis, E. & Pons, G. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br. J. Clin. Pharmacol. 68, 493-501 (2009).
4. Cella, M., Gorter de Vries, F., Burger, D., Danhof, M. & Della Pasqua, O. A model-based approach to dose selection in early pediatric development. Clin. Pharmacol. Ther. 87, 294-302 (2010).
5. Yuen, E., Gueorguieva, I., Wise, S., Soon, D. & Aarons, L. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J. Pharmacokinet. Pharmacodyn. 37, 3-24 (2010).
6. European Medicines Agency. Human Medicines Development and Evaluation. Concept paper on extrapolation of efficacy and safety in medicine development. EMA/129698/2012 (http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2012/06/WC500129285.pdf) (2012).
7. Bellanti, F. & Della Pasqua, O. Modelling and simulation as research tools in paediatric drug development. Eur. J. Clin. Pharmacol. 67 Suppl 1, 75-86 (2011).
8. Manolis, E., Rohou, S., Hemmings, R., Karlsson, M.O. & Milligan, P.A. How to use modelling and simulation in clinical development: Output from the EFPIA/EMA Modelling and Simulation Workshop. CPT Pharmacometrics Syst. Pharmacol., this issue.
9. Griffin, S., Bojke, L., Main, C. & Palmer, S. Incorporating direct and indirect evidence using bayesian methods: an applied case study in ovarian cancer. Value Health 9, 123-131 (2006). (Pubitemid 44044745)
10. Bauer, P. Statistical methodology relevant to the overall drug development program. Drug Inf. J. 37, 81-89 (2003). (Pubitemid 37305155)